Table 2.
Baseline – RA-specific characteristics
| RA, DMARD (n = 10) | RA, anti-TNF (n = 13) | p value | |
|---|---|---|---|
| ESR, mm/H | 9 [7–21] | 6 [6–17] | 0.689 |
| Disease activity score (DAS28) | 2.24 [1.3–2.5] | 1.98 [1.8–2.2] | 1.000 |
| Anti-CCP positive (%) | 7 (70) | 8 (61) | 0.673 |
| Rheumatoid factor positive (%) | 8 (80) | 7 (54) | 0.192 |
| Disease duration, years | 7.8 [4.0–10.2] | 13.3 [9.3–20.2] | 0.012 |
| Anti-TNF | n/a | n/a | |
| - Adalimumab | 10 | ||
| - Certolizumab | 1 | ||
| - Etanercept | 1 | ||
| Disease duration until start anti-TNF, years | 1.2 [1.0–1.7] | 5.6 [4.3–9.1] | 0.001 |
| Anti-TNF withdrawal attempts, yes/no | 10/0 | 9/4 | n/a |
| DMARD | n/a | ||
| - Methotrexate | 9 | 11 | |
| - Sulfasalazine | 1 | ||
| Other Rx | |||
| - Statin | 1 | 1 | 0.848 |
| - Antihypertensive | 5 | 5 | 0.580 |
Values are n (%), mean ± SD or median [IQR,] for skewed data
RA rheumatoid activity, DMARD disease-modifying antirheumatic drug, TNF tumor necrosis factor, ESR erythrocyte sedimentation rate, DAS28 disease activity score based on 28 joints, CCP cyclic citrullinated peptide